LOGIN  |  REGISTER
Amneal Pharmaceuticals
Chimerix

BrightSpring Health Services to Participate in Two Upcoming Investor Conferences

November 21, 2024 | Last Trade: US$33.49 0.44 1.33

LOUISVILLE, Ky., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that Company management will participate at two upcoming virtual investor conferences.

  • BTIG Virtual Digital Health Forum
    Panel on Monday, November 25th at 9:00AM ET
  • Bank of America Virtual Home Care Conference 2024
    Fireside Chat on Tuesday, December 10th at 2:10PM ET

A live and archived webcast of the Bank of America Home Care Conference Fireside Chat will be available on the “Event & Presentations” section of the BrightSpring investor relations website at https://ir.brightspringhealth.com/.

About BrightSpring Health Services

BrightSpring Health Services provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through the Company’s service lines, including pharmacy, home health care and primary care, and rehabilitation and behavioral health, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.

Contact

Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media Contact:
Leigh White
This email address is being protected from spambots. You need JavaScript enabled to view it. 
502.630.7412

Assertio

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page